<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601988</url>
  </required_header>
  <id_info>
    <org_study_id>TJCC007</org_study_id>
    <nct_id>NCT03601988</nct_id>
  </id_info>
  <brief_title>Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer</brief_title>
  <official_title>A Randomized Phase III Trial of Postoperative Chemotherapy or Chemo-radiotherapy for Locally Advanced Gastric Cancer After D2 Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy of adjuvant radiotherapy for D2 resected
      gastric cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The radiotherapy dose of 45Gy in 25 fractions as adjuvant treatment after D2 surgery for
      gastric cancer
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 28, 2018</start_date>
  <completion_date type="Anticipated">July 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All patients randomized to receive chemotherapy or chemo-radiotherapy after D2 surgery</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>36 months</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>36 months</time_frame>
    <description>From date of randomization until the date of first documented death from any cause, assessed up to 36 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemo-radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent chemo-radiotherapy</intervention_name>
    <description>Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy</description>
    <arm_group_label>Chemo-radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy group receive 8 cycles of XELOX.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-75；

          2. Had histologically confirmed adenocarcinoma of the stomach or gastroesophageal
             junction；

          3. ECOG 0-1；

          4. Subjects has to voluntarily join the study and sign the Informed Consent Form for the
             study;

          5. D2 and R0 resection;

          6. Locally advanced (UICC stage, T4, N2, N3) gastric cancer after surgery;

          7. More than 15 lymph nodes;

          8. Adequate organ function as defined below: Hematologic ANC ≥ 2*109/L, Platelets ≥
             100*109/L, AST and ALT ≤ 2.5×ULN, TBIL ≤ 1.5×ULN.

        Exclusion Criteria:

          1. Previous radiotherapy or chemotherapy；

          2. Inadequate organ function;

          3. Pregnant or lactating women or women of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianglin Yuan, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianglin Yuan, MD,PhD</last_name>
    <phone>8627-83663406</phone>
    <email>xlyuan1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Peng, PhD,MD</last_name>
    <phone>8627-83663407</phone>
    <email>pengpingtj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, MD,PHD</last_name>
      <phone>8627-83663406</phone>
      <phone_ext>1</phone_ext>
      <email>xlyuan1020@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ping Peng, MD,PHD</last_name>
      <phone>8627-83663407</phone>
      <phone_ext>1</phone_ext>
      <email>pengpingtj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xianglin Yuan, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ping Peng, MD,PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5.</citation>
    <PMID>25559811</PMID>
  </reference>
  <reference>
    <citation>Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977.</citation>
    <PMID>17978289</PMID>
  </reference>
  <reference>
    <citation>Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5. Epub 2014 Oct 15.</citation>
    <PMID>25439693</PMID>
  </reference>
  <reference>
    <citation>Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30.</citation>
    <PMID>11547741</PMID>
  </reference>
  <reference>
    <citation>Kim Y, Park SH, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Lee SJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK. The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. J Gastric Cancer. 2016 Jun;16(2):105-10. doi: 10.5230/jgc.2016.16.2.105. Epub 2016 Jun 24.</citation>
    <PMID>27433396</PMID>
  </reference>
  <reference>
    <citation>Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012 Jan 20;30(3):268-73. doi: 10.1200/JCO.2011.39.1953. Epub 2011 Dec 19.</citation>
    <PMID>22184384</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 15, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 25, 2018</last_update_submitted>
  <last_update_submitted_qc>July 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianglin Yuan</investigator_full_name>
    <investigator_title>Professor, Head of the cancer center</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

